Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Non-alcoholic Steatohepatitis (NASH)
... at a CAGR of 55.7% over the analysis period 2024-2030. Vitamin E & Pioglitazone Drugs, one of the segments analyzed in the report, is expected to record a 45.3% CAGR and reach US$59.7 Billion by ... Read More
-
Pharmaceutical Hot Melt Extrusion Equipment
... Million by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Twin Screw Extruders, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$28.0 ... Read More
-
Calcium Channel Blockers
... at a CAGR of 6.1% over the analysis period 2024-2030. Dihydropyridine Drugs, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$17.1 Billion by the end of ... Read More
-
Manual Filling Equipment
... at a CAGR of 6.7% over the analysis period 2024-2030. Food & Beverages End-Use, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.1 Billion by the ... Read More
-
Alpha-1 Antitrypsin Drugs
... at a CAGR of 9.6% over the analysis period 2024-2030. Prolastin C Drugs, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$2.1 Billion by the end ... Read More
-
Ampoules Packaging
... CAGR of 6.2% over the analysis period 2024-2030. Glass Material, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$5.6 Billion by the end of the analysis ... Read More
-
Antifungal Drugs
... CAGR of 4.2% over the analysis period 2024-2030. Azoles, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$10.7 Billion by the end of the analysis period. ... Read More
-
Bioburden Testing
... CAGR of 11.3% over the analysis period 2024-2030. Bioburden Testing Consumables, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.5 Billion by the end of the ... Read More
-
Dosing Systems
... CAGR of 4.6% over the analysis period 2024-2030. Diaphragm Dosing Systems, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$5.6 Billion by the end of the ... Read More
-
Carglumic Acid
... CAGR of 5.3% over the analysis period 2024-2030. Orally Disintegrating Tablets Delivery, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$105.6 Million by the end of ... Read More
-
Anti-Allergy Drugs
... CAGR of 7.1% over the analysis period 2024-2030. Pharmacies End-Use, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$35.4 Billion by the end of the analysis ... Read More
-
Beta-Sitosterol
... 8.1% over the analysis period 2024-2030. Food Ingredients Application, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$510.6 Million by the end of the analysis period. ... Read More
-
Antibiotics
... 3.1% over the analysis period 2024-2030. Penicillin, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth in ... Read More
-
Anticholinergic Drugs
... CAGR of 5.0% over the analysis period 2024-2030. Synthetic Compounds, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$6.6 Billion by the end of the analysis ... Read More
-
Sodium Alginate
... CAGR of 5.0% over the analysis period 2024-2030. Stabilizers Application, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$137.4 Million by the end of the analysis ... Read More
-
Personalized Nutrition
... CAGR of 13.5% over the analysis period 2024-2030. Active Measurement, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$27.5 Billion by the end of the analysis ... Read More
-
Pharmaceutical Cartridges
... CAGR of 6.8% over the analysis period 2024-2030. GlassMaterial, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$2.0 Billion by the end of the analysis period. ... Read More
-
Urothelial Cancer Drugs
... at a CAGR of 20.7% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$13.3 Billion by the end of the ... Read More
-
Nanocapsules
... 6.3% over the analysis period 2024-2030. Oncology Therapy Area, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis period. ... Read More
-
Epilepsy Drugs
... CAGR of 3.8% over the analysis period 2024-2030. First Generation Drugs, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$1.6 Billion by the end of the ... Read More
-
Bio Decontamination
... CAGR of 4.5% over the analysis period 2024-2030. Bio Decontamination Equipment, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$122.1 Million by the end of the ... Read More
-
Healthcare Contract Research Organization (CRO)
... Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Clinical CRO, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$68.2 Billion ... Read More
-
Healthcare Distribution
... CAGR of 13.5% over the analysis period 2024-2030. Pharmaceutical Distribution, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$2.3 Trillion by the end of the analysis ... Read More
-
Human Growth Hormone Drugs
... 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Subcutaneous Administration, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$3.4 Billion by the ... Read More
-
Active Pharmaceutical Ingredients (API)
... 2030, growing at a CAGR of 6.3% over the analysis period 2024-2030. Innovative APIs, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$240.8 Billion by the ... Read More
Research Assistance
